Treatment of thyroid carcinoma cells with four different suicide Gene/prodrug combinations in vitro

Anticancer Research

Volumn 18, Issue 3 A, 1998, Pages 1521-1525

  Nishihara, Eijun ^a   Nagayama, Yuji ^b   Narimatsu, Masaharu ^b   Namba, Hiroyuki ^a   Watanabe, Mitsuaki ^b   Niwa, Masami ^b   Yamashita, Shunichi ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Bystander effect; CB1954; Cytosine deaminase; Deoxycytidine kinase; Ganciclovir; Herpes simplex virus thymidine kinase; Nitroreductase

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; CYTARABINE; CYTOSINE DEAMINASE; DEOXYCYTIDINE KINASE; FLUOROURACIL; GANCICLOVIR; NITROREDUCTASE; PRODRUG; THYMIDINE KINASE;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ESCHERICHIA COLI; EXPRESSION VECTOR; GENE THERAPY; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RETROVIRUS; SUICIDE GENE; THYROID CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AZIRIDINES; CELL SURVIVAL; CYTARABINE; CYTOSINE DEAMINASE; DEOXYCYTIDINE KINASE; ESCHERICHIA COLI; FLUCYTOSINE; GANCICLOVIR; GENETIC VECTORS; HUMANS; NITROREDUCTASES; NUCLEOSIDE DEAMINASES; PRODRUGS; RECOMBINANT PROTEINS; RETROVIRIDAE; SIMPLEXVIRUS; THYMIDINE KINASE; THYROID NEOPLASMS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0031858735     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Connors TA: The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther 2: 702-709, 1995.
2. Roth JA and Cristiano RJ: Gene therapy for cancer: what have we done and where are we going? J. Natl Cancer Inst 81: 21 -39, 1997.
3. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46: 5276-5281, 1986.
4. Mullen CA, Kilstrup M and Blaese RM: Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 89: 33-37, 1992.
5. Chottiner EG, Shewach DS, Datta NS, Ashcraft E, Gribbin D, Ginsburg D, Fox IH and Mitchell BS: Cloning and expression of human deoxycytidine kinase cDNA. Proc Natl Acad Sci USA 88: 1531-1535, 1991.
6. Bridgewater JA, Springer CJ, Knox RJ, Minton NP, Mitchell NP and Collins MK: Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer 31A: 2362-2370, 1995.
7. Nishihara E, Nagayama Y, Mawatari F, Tanaka K, Namba H, Niwa M and Yamashita S: Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo. Endocrinology 138: 4577-4583, 1997.
8. Miller AD and Rosman GJ: Improved retroviral vectors for gene transfer and expression. Biotechniques 7: 980-990, 1989.
9. Studier FW, Rosenberg AH, Dunn JJ and Dubendorff JW: Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol 185: 60-89, 1990.
10. Zenno S, Koike H, Tanokura M and Saigo K: Gene cloning, purification, and characterization of NfsB, a minor oxygen-insensitive nitroreductase from Escherichia coli, similar in biochemical properties to FRase 1, the major flavin reductase in Vibrio fischeri. J Biochem 120: 736-744, 1996.
11. Goldstein H and Stamm R: Sur l'acide dinitro-4,6-chloro-3-benzoique. Helv ChimActa 165: 1330-1333, 1952.
12. Khan AH and Ross WCJ: Tomour-growth inhibitory nitro-phenylaziridines and related compounds: structure-activity relationships. Chem-Biol Interactions 70: 27-147, 1986.
13. Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL and Abraham GN: The "bystander effecr": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53: 5274-5283, 1993.
14. Hoganson DK, Batra RK, Olsen JC and Boucher RC: Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res 56: 1315-1323, 1996.
15. Rogers RP, Ge J-Q, Holley-Guthrie E, Hoganson DK, Comstock KE, Olsen JC and Kenney S: Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase. Hum Gene Ther 7: 2235-2245, 1996.
16. Trinh QT, Austin EA, Murray DM, Knick VC and Huber BE: Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 55: 4808-4812, 1995.
17. Li Z, Shanmugam N, Katayose D, Huber B, Srivastava S, Cowan K and Seth P: Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase. Cancer Gene Ther 4: 113-117, 1997.
18. Bridgewater JA, Knox RJ, Pitis JD, Collins MK and Springer CJ: The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell- permeable metabolite. Hum Gene Ther 8: 709-717, 1997.
19. Mesnil M, Piccoli C, Tiraby G, Willecke K and Yamasaki H: Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA 93: 1831-1835, 1996.
20. Wallace H, Ledent C, Vassart G, Bishop JO and al-Shawi R: Specific ablation of thyroid follicle cells in adult transgenic mice. Endocrinology 129: 3217-3226, 1991.
21. Ge K, Xu L, Zheng Z, Xu D, Sun L and Liu X: Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine. Int J Cancer 71: 675-679, 1997.
22. Gutler RE, Blair AD and Kelly MR: Fluorocytosine kineties in subjects with normal and impaired renal function. Clin Pharmacol Ther 24: 333-342, 1978.